Evidence map›Paper›PMID 36316010›Full record

GuidelineEuropean heart journal. Quality of care & clinical outcomes2022

European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment.

G A Lee, S Aktaa, E Baker, C P Gale, Israa F Yaseen, G Gulati, R Asteggiano, S Szmit, A Cohen-Solal, A Abdin and 17 more

Abstract readPractice GuidelineSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Guideline in European heart journal. Quality of care & clinical outcomes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Integrated Cardio-oncology Service.Cardiac failure review · 2026
    Review
  6. Article
  7. Article
  8. Review
  9. Cardio-oncology: chances and challenges.Basic research in cardiology · 2025
    Review
  10. Article
  11. Article
  12. Review
  13. The Role of Nursing in the Delivery of Cardio-Oncology.Current treatment options in oncology · 2024
    Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Left Ventricular Thrombus in Oncology Patients and Beyond: Imaging, Treatment Choices, and Duration.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

G A LeeDivision of Applied Technology for Clinical Care, Florence Nightingale Faculty of Nursing, Midwifery & Palliative Care, King's College London, James Clerk Maxwell Building, 57 Waterloo Road, London SE1 8WA, UK.ORCID 0000-0001-6385-8600
S AktaaLeeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.ORCID 0000-0002-9854-481X
E BakerDivision of Applied Technology for Clinical Care, Florence Nightingale Faculty of Nursing, Midwifery & Palliative Care, King's College London, James Clerk Maxwell Building, 57 Waterloo Road, London SE1 8WA, UK.
C P GaleLeeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.
Israa F YaseenBaghdad Heart Center, Baghdad Teaching Hospital, Medical City, Baghdad, Iraq.
G GulatiInstitute of Clinical Medicine, University of Oslo, Oslo, Norway, Division of Research and Innovation, Akershus University Hospital, Lørenskog, Norway.ORCID 0000-0002-1316-8676
R AsteggianoSchool of Medicine, Insubria University, Varese, Italy.ORCID 0000-0002-2273-7228
S SzmitDepartment of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, Centre of Postgraduate Medical Education, Otwock, Poland.ORCID 0000-0002-3075-1943
A Cohen-SolalResearch Medical Unit INSERM U-942, University of Paris, Paris, France.ORCID 0000-0003-1055-2231
A AbdinDepartment of Internal Medicine III, Cardiology, Angiology, Intensive Care Medicine, Saarland University Medical Center, Homburg, Germany.
W JurczakMSC National Research Institute of Oncology, Garnarska 11, 31-115 Krakow, Poland.
P Garrido LopezJefe Servicio Oncología Médica, Hospital Universitario Ramón y Cajal, Madrid, Spain.ORCID 0000-0002-5899-6125
A L SverdlovNewcastle Centre of Excellence in Cardio-Oncology, Calvary Mater Newcastle, Hunter Medical Research Institute, John Hunter Hospital, University of Newcastle, NSW, Australia.
C G TocchettiCardio-Oncology Unit, Department of Translational Medical Sciences (DISMET), Center for Basic and Clinical Immunology Research (CISI), Interdepartmental Center for Clinical and Translational Research (CIRCET), Interdepartmental Hypertension Research Center (CIRIAPA), Federico II University, Naples, Italy.
A BaracCardio-oncology Program, MedStar Heart and Vascular Institute, Washington DC, USA.ORCID 0000-0002-9935-8904
I ParriniDepartment of Cardiology, Mauriziano Hospital, Turin, Italy.
P ZamoranoUniversity Hospital Ramon y Cajal, Madrid, Spain.
Z IakobishviliDepartment of Community Cardiology, Clalit Health Services, Tel Aviv Jaffa, Israel.
R PudilUniversity Hospital Hradec Králové, Sokolská 5005, Hradec Králové, Czech Republic.
L BadimonIIBSant Pau, Hospital de la Santa Creu i Sant Pau, CiberCV, Barcelona, Spain.
A M KirbyRoyal Marsden NHS Trust & Institute of Cancer Research, London, UK.
A H BlaesDivision of Hematology/Oncology/Transplantation, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0002-5433-4810
D FarmakisUniversity of Cyprus Medical School, Nicosia, Cyprus.ORCID 0000-0001-8364-3447
G CuriglianoDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
R StephensPatient Advocate, London, UK.
A R LyonNational Heart and Lung Institute, Imperial College London, and Cardio-Oncology Service, Royal Brompton Hospital, London, UK.
T Lopez-FernandezCardiology department, La Paz University Hospital, IdiPAZ Research Institute, Madrid, Spain.

Funding

Cancer Research UK 28284
6 · The paper itself

Abstract

aimsTo develop quality indicators (QIs) for the evaluation of the prevention and management of cancer therapy-related cardiovascular toxicity. METHODS AND

resultsWe followed the European Society of Cardiology (ESC) methodology for QI development which comprises (i) identifying the key domains of care for the prevention and management of cancer therapy-related cardiovascular toxicity in patients on cancer treatment, (ii) performing a systematic review of the literature to develop candidate QIs, and (iii) selecting of the final set of QIs using a modified Delphi process. Work was undertaken in parallel with the writing of the 2022 ESC Guidelines on Cardio-Oncology and in collaboration with the European Haematology Association, the European Society for Therapeutic Radiology and Oncology and the International Cardio-Oncology Society. In total, 5 main and 9 secondary QIs were selected across five domains of care: (i) Structural framework, (ii) Baseline cardiovascular risk assessment, (iii) Cancer therapy related cardiovascular toxicity, (iv) Predictors of outcomes, and (v) Monitoring of cardiovascular complications during cancer therapy.

conclusionWe present the ESC Cardio-Oncology QIs with their development process and provide an overview of the scientific rationale for their selection. These indicators are aimed at quantifying and improving the adherence to guideline-recommended clinical practice and improving patient outcomes.

Indexed as

CardiologyNeoplasmsHumansMedical OncologyQuality Indicators, Health CareAssessmentCancer therapy-related cardiovascular toxicityCardio-oncologyOutcomesQuality indicatorsTreatment

Identifiers

PMID36316010
PMCPMC9745663

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.